Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment. We show 13 historical shares outstanding datapoints in our TERN shares outstanding history coverage, used to compute TERN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TERN market cap history over the course of time is important for investors
interested in comparing TERN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TERN versus a peer is one thing; comparing
TERN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TERN can fluctuate over the course of history.
With this page we aim to empower investors researching TERN by allowing them to research the TERN market cap history. |
Free TERN Email Alerts:
Video: The Importance of Market Cap
